Skip to main content
Fig. 1 | BMC Musculoskeletal Disorders

Fig. 1

From: Cyclic bisphosphonate therapy reduces pain and improves physical functioning in children with osteogenesis imperfecta

Fig. 1

Mean pain scores over time by osteogenesis imperfecta (OI) type, assessed by FACES® visual analogue scale immediately pre- / immediately post-infusion, 4 weeks post-infusion, and immediately pre- / immediately post subsequent infusion. Scale reduced (maximum pain score 5) for visual effect. * P < 0.001 for effect over time in all patients. ** P = 0.023 for difference in pain over time between patients with milder (Type I) and more severe (Types III/IV) OI

Back to article page

BMC Musculoskeletal Disorders

ISSN: 1471-2474

Contact us